Related Experiment Videos
Acute myocardial failure during Yersinia enterocolitica infection
Intensive Care Medicine
|January 1, 1982
Abstract:
A case of severe cardiac failure during generalized Yersinia enterocolitica infection, in a previously healthy woman is described. It was possible to demonstrate the important role of coronary hypoperfusion in the late stages of septic shock. When beta stimulant drugs became ineffective, IABP improved cardiac function.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Penile hemangiosarcoma as a cause of stranguria in a dog: clinical presentation, imaging findings, treatment and outcome.
Iranian journal of veterinary research·2024
Vaginal birth after prior myomectomy.
European journal of obstetrics, gynecology, and reproductive biology·2018
Essential strategies in HAI prevention and control: performance assessment through the implementation of the HAI-CoSIP tool of the GISIO-SItI group. A pilot study in a sample of Italian Organizations.
Annali di igiene : medicina preventiva e di comunita·2018
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Seminars in arthritis and rheumatism·2018
Definition of criteria and indicators for the prevention of Healthcare-Associated Infections (HAIs) in hospitals for the purposes of Italian institutional accreditation and performance monitoring.
Annali di igiene : medicina preventiva e di comunita·2017
ARDS management beyond the guidelines: a practical physiology-based approach to individualized care.
Intensive care medicine·2026
Corticosteroids in ARDS: old controversies, new insights, and future directions.
Intensive care medicine·2026
Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.
British journal of haematology·2026
iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer's disease immunotherapy.
Advances in immunology·2026
Expanding the therapeutic landscape of Still's disease: the emerging role of JAK inhibitors.
Expert opinion on pharmacotherapy·2026